1.Molecular pathological mechanism of liver metabolic disorder in mice with severe spinal muscular atrophy.
Lihe LIU ; Mingrui ZHU ; Yifan WANG ; Bo WAN ; Zhi JIANG
Journal of Southern Medical University 2023;43(5):852-858
		                        		
		                        			OBJECTIVE:
		                        			To explore the molecular pathological mechanism of liver metabolic disorder in severe spinal muscular atrophy (SMA).
		                        		
		                        			METHODS:
		                        			The transgenic mice with type Ⅰ SMA (Smn-/- SMN20tg/2tg) and littermate control mice (Smn+/- SMN20tg/2tg) were observed for milk suckling behavior and body weight changes after birth. The mice with type Ⅰ SMA mice were given an intraperitoneal injection of 20% glucose solution or saline (15 μL/12 h), and their survival time was recorded. GO enrichment analysis was performed using the RNA-Seq data of the liver of type Ⅰ SMA and littermate control mice, and the results were verified using quantitative real-time PCR. Bisulfite sequencing was performed to examine CpG island methylation level in Fasn gene promoter region in the liver of the neonatal mice.
		                        		
		                        			RESULTS:
		                        			The neonatal mice with type Ⅰ SMA showed normal milk suckling behavior but had lower body weight than the littermate control mice on the second day after birth. Intraperitoneal injection of glucose solution every 12 h significantly improved the median survival time of type Ⅰ SMA mice from 9±1.3 to 11± 1.5 days (P < 0.05). Analysis of the RNA-Seq data of the liver showed that the expression of the target genes of PPARα related to lipid metabolism and mitochondrial β oxidation were down-regulated in the liver of type Ⅰ SMA mice. Type Ⅰ SMA mice had higher methylation level of the Fasn promoter region in the liver than the littermate control mice (76.44% vs 58.67%). In primary cultures of hepatocytes from type Ⅰ SMA mice, treatment with 5-AzaC significantly up-regulated the expressions of the genes related to lipid metabolism by over 1 fold (P < 0.01).
		                        		
		                        			CONCLUSION
		                        			Type Ⅰ SMA mice have liver metabolic disorder, and the down-regulation of the target genes of PPARα related to lipid and glucose metabolism due to persistent DNA methylation contributes to the progression of SMA.
		                        		
		                        		
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Animals
		                        			;
		                        		
		                        			PPAR alpha
		                        			;
		                        		
		                        			Liver Diseases
		                        			;
		                        		
		                        			Muscular Atrophy, Spinal/genetics*
		                        			;
		                        		
		                        			Mice, Transgenic
		                        			;
		                        		
		                        			Body Weight
		                        			;
		                        		
		                        			Glucose
		                        			
		                        		
		                        	
2.Mechanisms of Dangua Recipe in Improving Glycolipid Metabolic Disorders Based on Transcriptomics.
Xian-Pei HENG ; Zhi-Ta WANG ; Liang LI ; Liu-Qing YANG ; Su-Ping HUANG
Chinese journal of integrative medicine 2022;28(2):130-137
		                        		
		                        			OBJECTIVE:
		                        			To explore the mechanisms of Dangua Recipe (DGR) in improving glycolipid metabolism based on transcriptomics.
		                        		
		                        			METHODS:
		                        			Sprague-Dawley rats with normal glucose level were divided into 3 groups according to a random number table, including a conventional diet group (Group A), a DGR group (Group B, high-calorie diet + 20.5 g DGR), and a high-calorie fodder model group (Group C). After 12 weeks of intervention, the liver tissue of rats was taken. Gene sequence and transcriptional analysis were performed to identify the key genes related to glycolipid metabolism reflecting DGR efficacy, and then gene or protein validation of liver tissue were performed. Nicotinamide phosphoribosyl transferase (Nampt) and phosphoenolpyruvate carboxykinase (PEPCK) proteins in liver tissues were detected by enzyme linked immunosorbent assay, fatty acid synthase (FASN) protein was detected by Western blot, and fatty acid binding protein 5 (FABP5)-mRNA was detected by quantitative real-time polymerase chain reaction. Furthermore, the functional verification was performed on the diabetic model rats by Nampt blocker (GEN-617) injected in vivo. Hemoglobin A
		                        		
		                        			RESULTS:
		                        			Totally, 257 differential-dominant genes of Group A vs. Group C and 392 differential-dominant genes of Group B vs. Group C were found. Moreover, 11 Gene Ontology molecular function terms and 7 Kyoto Encyclopedia of Genes and Genomes enrichment pathways owned by both Group A vs. Group C and Group C vs. Group B were confirmed. The liver tissue target validation showed that Nampt, FASN, PEPCK protein and FABP5-mRNA had the same changes consistent with transcriptome. The in vivo functional tests showed that GEN-617 increased body weight, HbA
		                        		
		                        			CONCLUSION
		                        			Nampt activation was one of the mechanisms about DGR regulating glycolipid metabolism.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Diabetes Mellitus, Experimental
		                        			;
		                        		
		                        			Drugs, Chinese Herbal
		                        			;
		                        		
		                        			Glycolipids
		                        			;
		                        		
		                        			Liver
		                        			;
		                        		
		                        			Metabolic Diseases
		                        			;
		                        		
		                        			Rats
		                        			;
		                        		
		                        			Rats, Sprague-Dawley
		                        			;
		                        		
		                        			Transcriptome/genetics*
		                        			
		                        		
		                        	
3.Analysis of 6 cases with hepatocerebral mitochondrial DNA depletion syndrome and literature review.
Mei Xi ZHAO ; Jian She WANG ; Jing Yu GONG
Chinese Journal of Pediatrics 2022;60(5):457-461
		                        		
		                        			
		                        			Objective: To explore the clinical features of hepatocerebral mitochondrial DNA depletion syndrome (MDS). Methods: The clinical data of 6 hepatocerebral MDS patients diagnosed in the Jinshan Hospital of Fudan University from January 2012 to December 2019 were retrospectively collected and analyzed. Related literature published before January 2020 were searched with the key words of "DGUOK""MPV17""POLG""C10orf2" in PubMed, China national knowledge infrastructure (CNKI) and Wanfang database. Results: All the 6 hepatocerebral MDS cases were male. The age of onset ranged from 3 days to 8 months. The most common initial symptoms were cholestasis and developmental retrogression. The main clinical manifestations included hepatomegaly (4 cases), hypotonia (3 cases), growth retardation (4 cases), cholestasis (5 cases), coagulopathy (5 cases), hypoalbuminemia (3 cases), hypoglycemia (4 cases), hyperlactacidemia (5 cases), and abnormal blood metabolism screening (6 cases). The isotope hepatobiliary imaging revealed no gallbladder and intestinal tract development within 24 hours in 2 patients. Regarding the cranial imaging examination, the head CT found widening of the extracranial space in 1 case, the brain magnetic resonance imaging (MRI) found ventricular enlargement in 2 cases, and the brain ultrasound found peripheral white matter injury in 1 case. Two cases were lost to follow-up, one died of liver failure, and three died of multiple organ failure due to aggravated infection. Among the 6 cases, there were 3 with MPV17 variation (c.182T>C and c.279G>C were novel), 1 with POLG variation (c.2993G>A was novel), 1 with DGUOK variation (c.679G>A homozygous mutation, parthenogenetic diploid of chromosome 2) and 1 with C10orf2 variation (c.1186C>T and c.1504C>T were novel). The literature review found that 129, 100, 51 and 12 cases of hepatocerebral MDS were caused by DGUOK, MPV17, POLG and C10orf2 gene variations, respectively. And the most common clinical manifestations were liver dysfunction presented with cholestasis and elevated transaminase, metabolic disorders including hypoglycemia and hyperlactacidemia, and diverse neurologic symptoms including developmental retardation, hypotonia, epilepsy and peripheral neuropathy. Besides, 1/3 of the patients with C10orf2 variation developed renal tubular injury. Conclusions: Hepatocerebral MDS mainly present with liver dysfunction, metabolic disorder and neuromuscular impairment. Different genotypes show specific clinical manifestations.
		                        		
		                        		
		                        		
		                        			Cholestasis
		                        			;
		                        		
		                        			DNA, Mitochondrial/genetics*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hypoglycemia/genetics*
		                        			;
		                        		
		                        			Infant
		                        			;
		                        		
		                        			Liver Diseases/genetics*
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Mitochondrial Diseases
		                        			;
		                        		
		                        			Muscle Hypotonia
		                        			;
		                        		
		                        			Retrospective Studies
		                        			
		                        		
		                        	
4.Role of osteopontin in diet-induced brown gallstone formation in rats.
Chang-Guo JIN ; Feng-Ru JIANG ; Jie ZHANG ; Jun-Ren MA ; Xiao-Feng LING
Chinese Medical Journal 2021;134(9):1093-1100
		                        		
		                        			BACKGROUND:
		                        			Although osteopontin (OPN) is expressed in the liver and pigment gallstones of patients with hepatolithiasis, its role in pigment gallstone formation remains unclear. This study aimed to explore the function of OPN in pigment gallstone formation.
		                        		
		                        			METHODS:
		                        			Rats were fed a chow diet (CD) or lithogenic diet (LD) for 10 consecutive weeks; blocking tests were then performed using an OPN antibody (OPN-Ab). Incidence of gallstones and levels of several bile components, OPN, tumor necrosis factor alpha (TNF-α), and cholesterol 7 alpha-hydroxylase (CYP7A1) were analyzed. To determine TNF-α expression in hepatic macrophages and both CYP7A1 and bile acid (BA) expression in liver cells, recombinant rat OPN and recombinant rat TNF-α were used to treat rat hepatic macrophages and rat liver cells, respectively. Chi-square or Fisher exact tests were used to analyze qualitative data, Student t-test or one-way analysis of variance were used to analyze qualitative data.
		                        		
		                        			RESULTS:
		                        			Incidence of gallstones was higher in LD-fed rats than in CD-fed rats (80% vs. 10%, P < 0.05). BA content significantly decreased in bile (t = -36.08, P < 0.01) and liver tissue (t = -16.16, P < 0.01) of LD-fed rats. Both hepatic OPN protein expression (t = 9.78, P < 0.01) and TNF-α level (t = 8.83, P < 0.01) distinctly increased in the LD group; what's more, CYP7A1 mRNA and protein levels (t = -12.35, P < 0.01) were markedly down-regulated in the LD group. Following OPN-Ab pretreatment, gallstone formation decreased (85% vs. 25%, χ2 = 14.55, P < 0.01), liver TNF-α expression (F = 20.36, P < 0.01) was down-regulated in the LD group, and CYP7A1 expression (F = 17.51, P < 0.01) was up-regulated. Through CD44 and integrin receptors, OPN promoted TNF-α production in macrophage (F = 1041, P < 0.01), which suppressed CYP7A1 expression (F = 48.08, P < 0.01) and reduced liver BA synthesis (F = 119.4, P < 0.01).
		                        		
		                        			CONCLUSIONS
		                        			We provide novel evidence of OPN involvement in pigmented gallstone pathogenesis in rats.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Diet/adverse effects*
		                        			;
		                        		
		                        			Gallstones/etiology*
		                        			;
		                        		
		                        			Lithiasis
		                        			;
		                        		
		                        			Liver
		                        			;
		                        		
		                        			Liver Diseases
		                        			;
		                        		
		                        			Osteopontin/genetics*
		                        			;
		                        		
		                        			Rats
		                        			
		                        		
		                        	
5.Study on liver diseases with zebrafish as an important tool.
Zhi-Qi LI ; Yue XU ; Xia ZHAO ; Zhe JIA ; Zhao-Yi WANG ; Dan FENG ; Cui-Bai LI ; Zhi-Qiang MA ; Chong-Jun ZHAO ; Rui-Chao LIN
China Journal of Chinese Materia Medica 2021;46(2):320-332
		                        		
		                        			
		                        			With the increasing incidence of hepatobiliary diseases, it is particularly important to understand the role of molecular, cellular and physiological factors in the clinical diagnosis and treatment with traditional Chinese medicine(TCM) in the development of liver disease. Appropriate animal models can help us identify the possible mechanisms of relevant diseases. Danio rerio(zebrafish) model was traditionally used to study embryonic development, and has been gradually used in screening and evaluation of liver diseases and relevant drug in recent years. Zebrafish embryos develop rapidly and the digestive organs of 5-day-old juvenile fish are all mature. At this stage, they may develop hepatobiliary diseases induced by developmental defects or compounds. Zebrafish liver is similar to human liver in cell composition, function, signal transduction, response to injury and cell process mediating liver disease. Furthermore, due to the high conservation of genes and proteins between humans and zebrafish, zebrafish becomes an alternative system for studying basic mechanisms of liver disease. Therefore, genetic screening could be performed to identify new genes involving specific disease processes, and chemical screening could be made for drugs in specific processes. This paper briefly introduced the experimental properties of zebrafish as model system, emphasized the study progress of zebrafish models for pathological mechanism of liver diseases, especially fatty liver, and drug screening and evaluation, so as to provide ideas and techniques for the future liver toxicity assessment of TCM.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Drug Evaluation, Preclinical
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Liver
		                        			;
		                        		
		                        			Liver Diseases/genetics*
		                        			;
		                        		
		                        			Medicine, Chinese Traditional
		                        			;
		                        		
		                        			Zebrafish/genetics*
		                        			
		                        		
		                        	
6.Liver Involvement in Children with Alpha-1 Antitrypsin Deficiency: A Multicenter Study
Murat CAKIR ; Elif SAG ; Ali ISLEK ; Masallah BARAN ; Gokhan TUMGOR ; Sema AYDOGDU
Pediatric Gastroenterology, Hepatology & Nutrition 2020;23(2):146-153
		                        		
		                        			
		                        			PURPOSE: Alpha-1 antitrypsin deficiency (A1ATD) in one of the most common genetic causes of liver disease in children. We aimed to analyze the clinical characteristics and outcomes of patients with A1ATD.METHODS: This study included patients with A1ATD from five pediatric hepatology units. Demographics, clinical findings, genetics, and outcome of the patients were recorded (n=25).RESULTS: Eight patients (32.0%) had homozygous PiZZ genotype while 17 (68.0%) had heterozygous genotype. Patients with PiZZ genotype had lower alpha-1 antitrypsin levels than patients with PiMZ genotype (37.6±7.7 mg/dL vs. 66.5±22.7 mg/dL, p=0.0001). Patients with PiZZ genotype were diagnosed earlier than patients with PiMZ genotype, but this was not significant (13±6.8 months vs. 23.7±30.1 months, p=0.192). Follow-up revealed the death of one patient (12.5%) with a homozygous mutation, and revealed that one patient had child A cirrhosis, five patients (62.5%) had chronic hepatitis, and one patient (12.5%) was asymptomatic. Nine of the 17 patients with a heterozygous mutation had chronic hepatitis (52.9%), two (11.7%) had child A cirrhosis, and six (35.2%) were asymptomatic. Overall, 18 (72%) of the 25 children had liver pathology in the long-term.CONCLUSION: Although prevalence is rare, patients with liver disorders should be checked for alpha-1 antitrypsin levels. Moreover, long-term follow-up is essential because most patients have a liver pathology.
		                        		
		                        		
		                        		
		                        			Child
		                        			;
		                        		
		                        			Demography
		                        			;
		                        		
		                        			Fibrosis
		                        			;
		                        		
		                        			Follow-Up Studies
		                        			;
		                        		
		                        			Gastroenterology
		                        			;
		                        		
		                        			Genetics
		                        			;
		                        		
		                        			Genotype
		                        			;
		                        		
		                        			Hepatitis, Chronic
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Liver Diseases
		                        			;
		                        		
		                        			Liver
		                        			;
		                        		
		                        			Pathology
		                        			;
		                        		
		                        			Prevalence
		                        			;
		                        		
		                        			Prognosis
		                        			
		                        		
		                        	
7.EGFR-TKI ADR Management Chinese Expert Consensus.
Chinese Society of Lung Cancer, Chinese Anti-Cancer Association
Chinese Journal of Lung Cancer 2019;22(2):57-81
		                        		
		                        			
		                        			ErbB receptor tyrosine kinase inhibitors (EGFR-TKI), gefitinib, erlotinib, icotinib and aftinib, which are approved as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors harboring EGFR mutations in China. And osimertinib was approved in second line setting for patients with EGFRT 790M-positive NSCLC. Rash, paronychia, diarrhea, stomatitis, liver dysfunction and (interstitial lung disease, ILD) are frequently observed in patients treated with EGFR-TKI. Chinese Society of Lung Cancer, Chinese Anti-Cancer Association, organized Chinese experts to develop the Chinese expert consensus on EGFR-TKI adverse event (AE) management based on domestic diagnosis and treatment of ADR and also incorporating international updated theory and recommendations.
.
		                        		
		                        		
		                        		
		                        			Antineoplastic Agents
		                        			;
		                        		
		                        			adverse effects
		                        			;
		                        		
		                        			therapeutic use
		                        			;
		                        		
		                        			Carcinoma, Non-Small-Cell Lung
		                        			;
		                        		
		                        			drug therapy
		                        			;
		                        		
		                        			enzymology
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			China
		                        			;
		                        		
		                        			Diarrhea
		                        			;
		                        		
		                        			etiology
		                        			;
		                        		
		                        			ErbB Receptors
		                        			;
		                        		
		                        			antagonists & inhibitors
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Liver Diseases
		                        			;
		                        		
		                        			etiology
		                        			;
		                        		
		                        			Lung Diseases
		                        			;
		                        		
		                        			etiology
		                        			;
		                        		
		                        			Lung Neoplasms
		                        			;
		                        		
		                        			drug therapy
		                        			;
		                        		
		                        			enzymology
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			Protein Kinase Inhibitors
		                        			;
		                        		
		                        			adverse effects
		                        			;
		                        		
		                        			therapeutic use
		                        			;
		                        		
		                        			Stomatitis
		                        			;
		                        		
		                        			etiology
		                        			
		                        		
		                        	
8.New Perspectives in Pediatric Nonalcoholic Fatty Liver Disease: Epidemiology, Genetics, Diagnosis, and Natural History
Pediatric Gastroenterology, Hepatology & Nutrition 2019;22(6):501-510
		                        		
		                        			
		                        			Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in children. The global prevalence of pediatric NAFLD from general populations is 7.6%. In obese children, the prevalence is higher in Asia. NAFLD has a strong heritable component based on ethnic difference in the prevalence and clustering within families. Genetic polymorphisms of patatin-like phospholipase domain–containing protein 3 (PNPLA3), transmembrane 6 superfamily member 2, and glucokinase regulatory protein (GCKR) are associated with the risk of NAFLD in children. Variants of PNPLA3 and GCKR are more common in Asians. Alterations of the gut microbiome might contribute to the pathogenesis of NAFLD. High fructose intake increases the risk of NAFLD. Liver fibrosis is a poor prognostic factor for disease progression to cirrhosis. Magnetic resonance spectroscopy and magnetic resonance proton density fat fraction are more accurate for steatosis quantification than ultrasound. Noninvasive imaging methods to assess liver fibrosis, such as transient elastography, shear-wave elastography, and magnetic resonance elastography are useful in predicting advanced fibrosis, but they need further validation. Longitudinal follow-up studies into adulthood are needed to better understand the natural history of pediatric NAFLD.
		                        		
		                        		
		                        		
		                        			Asia
		                        			;
		                        		
		                        			Asian Continental Ancestry Group
		                        			;
		                        		
		                        			Child
		                        			;
		                        		
		                        			Diagnosis
		                        			;
		                        		
		                        			Disease Progression
		                        			;
		                        		
		                        			Elasticity Imaging Techniques
		                        			;
		                        		
		                        			Epidemiology
		                        			;
		                        		
		                        			Fibrosis
		                        			;
		                        		
		                        			Follow-Up Studies
		                        			;
		                        		
		                        			Fructose
		                        			;
		                        		
		                        			Gastrointestinal Microbiome
		                        			;
		                        		
		                        			Genetics
		                        			;
		                        		
		                        			Glucokinase
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Liver Cirrhosis
		                        			;
		                        		
		                        			Liver Diseases
		                        			;
		                        		
		                        			Magnetic Resonance Spectroscopy
		                        			;
		                        		
		                        			Microbiota
		                        			;
		                        		
		                        			Natural History
		                        			;
		                        		
		                        			Non-alcoholic Fatty Liver Disease
		                        			;
		                        		
		                        			Phospholipases
		                        			;
		                        		
		                        			Polymorphism, Genetic
		                        			;
		                        		
		                        			Prevalence
		                        			;
		                        		
		                        			Protons
		                        			;
		                        		
		                        			Ultrasonography
		                        			
		                        		
		                        	
9.Systems pharmacology-based investigation of Sanwei Ganjiang Prescription: related mechanisms in liver injury.
Yun-Xia LUO ; Xin-Yue WANG ; Yu-Jie HUANG ; Shu-Huan FANG ; Jun WU ; Yong-Bin ZHANG ; Tian-Qin XIONG ; Cong YANG ; Jian-Gang SHEN ; Chuan-Lan SANG ; Qi WANG ; Jian-Song FANG
Chinese Journal of Natural Medicines (English Ed.) 2018;16(10):756-765
		                        		
		                        			
		                        			Liver injury remains a significant global health problem and has a variety of causes, including oxidative stress (OS), inflammation, and apoptosis of liver cells. There is currently no curative therapy for this disorder. Sanwei Ganjiang Prescription (SWGJP), derived from traditional Chinese medicine (TCM), has shown its effectiveness in long-term liver damage therapy, although the underlying molecular mechanisms are still not fully understood. To explore the underlining mechanisms of action for SWGJP in liver injury from a holistic view, in the present study, a systems pharmacology approach was developed, which involved drug target identification and multilevel data integration analysis. Using a comprehensive systems approach, we identified 43 candidate compounds in SWGJP and 408 corresponding potential targets. We further deciphered the mechanisms of SWGJP in treating liver injury, including compound-target network analysis, target-function network analysis, and integrated pathways analysis. We deduced that SWGJP may protect hepatocytes through several functional modules involved in liver injury integrated-pathway, such as Nrf2-dependent anti-oxidative stress module. Notably, systems pharmacology provides an alternative way to investigate the complex action mode of TCM.
		                        		
		                        		
		                        		
		                        			Drugs, Chinese Herbal
		                        			;
		                        		
		                        			administration & dosage
		                        			;
		                        		
		                        			chemistry
		                        			;
		                        		
		                        			Gene Expression
		                        			;
		                        		
		                        			drug effects
		                        			;
		                        		
		                        			Hepatocytes
		                        			;
		                        		
		                        			drug effects
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Liver
		                        			;
		                        		
		                        			drug effects
		                        			;
		                        		
		                        			injuries
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Liver Diseases
		                        			;
		                        		
		                        			drug therapy
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Oxidative Stress
		                        			;
		                        		
		                        			drug effects
		                        			;
		                        		
		                        			Pharmacology
		                        			
		                        		
		                        	
10.Relationship between expression of peripheral blood HLA-DR, CD4CD25 regulatory T cells, IL-17 and IL-27 with liver damage in children with human cytomegalovrius infection.
Li-Li ZHU ; Ling XU ; Jun WANG
Chinese Journal of Contemporary Pediatrics 2018;20(7):554-558
OBJECTIVETo study the relationship between the expression of peripheral blood HLA-DR, CD4CD25 regulatory T cells, IL-17 and IL-27 with liver damage in children with human cytomegalovirus (HCMV) infection.
METHODSTwenty-one HCMV children with liver damage and twenty-one HCMV children without liver damage were enrolled in this study. The expression of peripheral blood HLA-DR and CD4CD25 regulatory T cells was detected by flow cytometry. Plasma levels of IL-17 and IL-27 were measured using ELISA.
RESULTSThe plasma levels of IL-17 and IL-27 in children with liver damage were significantly higher than in those without liver damage, while the expression of peripheral blood CD4CD25 regulatory T cells was lower than in those without liver damage (P<0.05). Plasma IL-17 and IL-27 levels were negatively correlated with the expression of peripheral blood CD4CD25 regulatory T cells (P<0.01).
CONCLUSIONSImmune imbalance mediated by CD4CD25 regulatory T cells and over-expression of IL-17 and IL-27 may be involved in the pathogenesis of liver damage in children with HCMV infection.
CD4 Antigens ; immunology ; Cytomegalovirus ; physiology ; Cytomegalovirus Infections ; blood ; complications ; genetics ; Female ; Flow Cytometry ; HLA-DR Antigens ; genetics ; immunology ; Humans ; Infant ; Interleukin-17 ; blood ; genetics ; Interleukin-2 Receptor alpha Subunit ; immunology ; Interleukins ; blood ; genetics ; Liver ; injuries ; metabolism ; Liver Diseases ; blood ; etiology ; immunology ; Male ; T-Lymphocytes, Regulatory ; immunology
            
Result Analysis
Print
Save
E-mail